Clinical Trial Update: Effects of Canagliflozin on Intravascular Volume and Hemodynamics [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the effects of canagliflozin on intravascular volume and hemodynamics has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Type 2 Diabetes Mellitus

Drugs mentioned

• Canagliflozin (canagliflozin)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Type2 Diabetes Mellitus, Cardiovascular Diseases | Phase 4 | Status: WITHDRAWN